Portal

📍 Watertown, United States🗓 Founded 2023👥 97 employees💰 Last funded May 2026
Biotechnology Research🌐 linkedin.com
Website LinkedIn
Portal is building the universal infrastructure for cell engineering across drug discovery and cell therapy. Our proprietary mechanical system enables efficient, scalable delivery of RNA, gene editors, probes, and other molecules into hard-to-transfect cells across many cell types and workflows. With more than 100 customer sites including the top 10 pharma, researchers use Portal to run high-throughput, physiologically relevant screens and de-risk targets earlier, while cell therapy developers leverage the platform to multi-engineer cells beyond the limits of viral or electroporation methods. Integrated with leading high-throughput robotics and with GMP manufacturing systems, Portal is powering both next-generation discovery and laying the groundwork for future point-of-care cell therapy manufacturing.
4
Total investors
3
Early stage
1
Mid stage
0
Late stage
2023
Founded

Investors

4 investors
All
Early stage
Mid stage
Late stage
Investor geography2 countries
Canada
2
United States
2
Investor activity2023–2026 · investors recorded per year
202322024120261
Recent (last 2y)Earlier
Frequently asked questions
Who invested in Portal?
Portal has 4 investors on record on gritt.io, including 3 early-stage backers, 1 mid-stage.
When did Portal last raise funding?
The most recent investment in Portal recorded on gritt.io was in May 2026.
When was Portal founded?
Portal was founded in 2023.
What industry is Portal in?
Portal operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Portal based?
Portal is headquartered in Watertown, United States.